B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Project Manager - Medical Affairs PMO

Full-TimeUpdated on 10/23/2026
No salary listed
Senior
Bachelor's
Seoul, South Korea
In PersonExtensive domestic, regional, and international travel may be required.
Project & Program ManagementProgram Management

About the job

Requirements
  • A bachelor's degree in life sciences, registered nurse qualification, or equivalent with significant healthcare-industry experience and a strong clinical, medical, or research background is required.
  • At least 7 years of experience in the pharmaceutical or biotechnology industry, including substantial project or program management experience, is required.
  • Knowledge of relevant regulatory and compliance requirements is required.
  • Excellent proficiency in Microsoft Office, including Excel, PowerPoint, and Word, is required.
  • Extensive domestic, regional, and international travel may be required.
Responsibilities
  • Support the development, review, and approval coordination of post-marketing and other Phase IV study concepts, synopses, protocols, informed consent forms, and safety management plans; lead development of case report forms, project-management documents, and other essential documents.
  • Lead contract research organization and vendor selection, quality review, contracting, study start-up, timeline planning, budget oversight, scope-change management, and operational risk management.
  • Serve as the primary operational contact for the contract research organization and oversee performance against contracted deliverables and key performance indicators, including site activation, enrollment, data milestones, reports, and close-out.
  • Coordinate with Medical Affairs, Regulatory Affairs, Pharmacovigilance, Quality Assurance, Procurement, Finance, global Medical Operations, and other relevant teams to support compliant execution and required submissions.
  • Coordinate review and approval of post-marketing study result reports, safety reports, and supporting documents, and provide finalized documents promptly to the local safety responsible person for timely Ministry of Food and Drug Safety submissions.
  • Lead or support planning, execution, and oversight of Korean real-world evidence and real-world data studies undertaken to fulfill post-approval, risk-management, reimbursement, payer, or other health-authority requirements or commitments, focusing on regulatory- or access-driven evidence-generation needs.
  • Provide operational and strategic input for observational studies, registries, database studies, chart reviews, and other fit-for-purpose real-world evidence approaches.
  • Coordinate feasibility, data-source and vendor assessment, study planning, contracting, budget management, timelines, deliverables, data quality, privacy considerations, and operational risk management throughout study lifecycles.
  • Collaborate with Medical Affairs, Epidemiology, Biostatistics, Health Economics and Outcomes Research, Regulatory Affairs, Pharmacovigilance, Legal, Compliance, Data Privacy, Quality Assurance, and external stakeholders as applicable.
  • Ensure real-world evidence and real-world data activities comply with approved protocols, applicable Korean requirements, relevant scientific and industry guidelines, data privacy requirements, and internal procedures.
  • Coordinate real-world evidence and real-world data communications, document packages, and responses to follow-up requests from regulatory agencies, payers, or other health authorities with relevant internal teams and external partners.
  • Support completion and submission readiness of study outputs, including final study reports, regulatory or reimbursement submission materials, responses to additional health-authority requirements, publications, and congress presentations.
  • Develop country compassionate-use and/or pre-reimbursement access program plans in alignment with global program teams and Korean requirements, in collaboration with the Medical Director and/or Therapeutic Area Lead.
  • Support development of local essential documents for early-access programs, including protocols, informed consent forms, patient information, operational plans, and required submission materials.
  • Lead and execute local early-access program start-up activities with the medical responsible person, including site selection, institutional review board submissions, contracting, investigational product shipment coordination, and readiness activities.
  • Manage early-access program and site activities to support timely and compliant delivery, excluding site monitoring or other on-site activities unless separately assigned and approved.
  • Prepare or coordinate final early-access program report submissions to the Ministry of Food and Drug Safety with the medical person responsible and Regulatory Affairs.
  • Lead operational processes for single-patient use requests in accordance with local requirements and in collaboration with the medical person responsible.
  • Collaborate with local Medical Affairs, Pharmacovigilance, Regulatory Affairs, Supply Chain Management, Quality Assurance, and relevant global teams on early-access programs.
  • Collaborate with the global investigator-initiated trial team, local field medical team, and relevant functions to support local project planning, governance alignment, and execution readiness in accordance with global processes and Korean health-authority requirements.
  • Provide country-level operational input to investigator-initiated trial planning, including Korean regulatory and local-practice requirements, feasibility, timelines, budgets, contracting, documentation, approvals, and operational risk management.
  • Establish or provide local tools, trackers, and governance support for investigator-initiated trial review, approval, contracting, milestone and payment tracking, study-status visibility, and document archiving in accordance with country regulations and company procedures.
  • Provide non-promotional operational support, communication frameworks, and practical tools to coordinate internal stakeholders, site staff, and principal investigators while maintaining investigator independence, Field Medical responsibilities, and applicable governance requirements.
  • Support country-level investigator-initiated trial governance by monitoring progress, identifying operational issues, facilitating resolution, and escalating material risks or delays to the relevant governance body.
  • Ensure Medical Affairs programs comply with applicable Korean laws and regulations, industry codes, data privacy requirements, company policies, standard operating procedures, approved plans, and contractual obligations.
  • Maintain complete, accurate, current, and inspection-ready program documentation in appropriate validated or access-controlled repositories.
  • Manage SharePoint or other approved repositories for project plans, approvals, contracts, invoices, meeting records, trackers, dashboards, final reports, and deliverables.
  • Coordinate required internal reviews and approvals, and maintain traceable documentation of decisions, actions, deviations, risks, and issue resolution.
  • Support audits, inspections, quality reviews, and compliance reporting as applicable.
  • Promote consistent document naming, version control, access management, retention, and archival practices across Korea Medical Affairs programs.
  • Track project budgets, purchase orders, invoices, milestone payments, scope changes, and financial risks; investigate variances and coordinate timely resolution with Finance and budget owners.
  • Maintain visibility into planned, committed, invoiced, accrued, and actual spending across Medical Affairs programs and cost categories.
  • Provide regular budget and spending reports to support prioritization, resource planning, and leadership decision-making.
  • Support annual operating plan activities, periodic forecast updates, accrual exercises, and other corporate finance requirements applicable to Korea Medical Affairs.
  • Lead or coordinate vendor identification, request-for-proposal activities, bid evaluation, vendor selection, qualification, contracting, and onboarding for Medical Affairs programs.
  • Collaborate with Procurement, Legal, Compliance, Quality Assurance, Finance, and business owners to complete contracts, statements of work, budgets, purchase orders, and required approvals before work begins.
  • Manage vendor performance against contracted scope, timelines, deliverables, quality expectations, key performance indicators, and budgets.
  • Coordinate change orders and scope changes, assess operational and financial impact, and ensure appropriate documentation and approval.
  • Resolve sourcing, contracting, vendor, and project-delivery issues, and drive timely resolution or escalation as appropriate.
  • Support vendor registration, contract approval requests, procurement and SAP processing, invoice review, and related administrative requirements as needed.
  • Facilitate alignment and effective communication across Medical Affairs, Regulatory Affairs, Pharmacovigilance, Quality Assurance, Supply Chain, Finance, Procurement, Legal, Compliance, Biostatistics, Epidemiology, and relevant global or regional teams.
  • Identify opportunities to simplify processes, improve operational efficiency, share best practices, and standardize project-management approaches and performance measures within Korea Medical Affairs.
  • Lead or contribute to departmental and organizational initiatives, new operating-model solutions, and other special projects assigned by the Country Medical Director.
  • Establish scalable tools, templates, trackers, dashboards, and meeting frameworks that improve transparency, accountability, and collaboration.
  • Identify recurring gaps, propose solutions, and use data and operational insights to support change management and adoption.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • Wellness Program
  • Paid Vacation

Growth & Insights and Company News

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.